Is Takeda Pharmaceutical (TSE:4502) Cheap On New Psoriasis Drug Data?

Takeda Pharmaceutical stock reaction to new psoriasis drug data

Takeda Pharmaceutical (TSE:4502) just put fresh Phase 3 data for its oral TYK2 inhibitor zasocitinib in front of dermatologists, showing superior psoriasis efficacy versus current oral options with a reported consistent safety profile.

At a share price of ¥5,797, Takeda Pharmaceutical has seen a 17.92% year to date share price return, while a 38.40% total shareholder return over one year and 122.40% over five years suggest that momentum has been building as investors respond to product updates such as the zasocitinib data and other pipeline progress.

Scan how Takeda Pharmaceutical compares with other drug makers riding similar clinical catalysts by reviewing our curated set of 10 healthcare AI stocks in the broader healthcare and AI-enabled research space.

Takeda Pharmaceutical now has a headline psoriasis asset and a share price that has already moved sharply. The next step is to see whether that story is already fully reflected in the valuation or not.

Most Popular Narrative: 12% Undervalued

On the numbers, the most followed narrative pegs Takeda Pharmaceutical’s fair value at ¥6,603 per share versus the last close of ¥5,797, framing the recent zasocitinib excitement inside a broader long term recovery story.

The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues. This would allow Takeda's core growth and launch products to drive top-line and earnings recovery going forward. Rapid progress and positive late-stage data from Takeda's innovative pipeline, especially in high-need therapeutic areas like rare diseases (orexin agonists for narcolepsy, rusfertide for polycythemia vera), set the stage for multiple high-value product launches. These can catalyze multi-year revenue and margin expansion.

See why 17 investors see Takeda Pharmaceutical as 12% undervalued.

Result: Fair Value of ¥6,603 (UNDERVALUED)

Still, the bullish Takeda Pharmaceutical narrative can unravel quickly if generic competition accelerates on key therapies or late stage pipeline assets fall short in pivotal data.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Another View: Takeda Pharmaceutical Through Sales Multiples

There is a very different signal once you step away from models built on future cash flows and look at what investors pay for Takeda Pharmaceutical’s current revenue. The stock trades on a P/S of roughly 2x, above the JP pharmaceuticals average of 1.6x, yet below both the peer group at 3.5x and an estimated fair ratio of 3.6x. That mix points to some valuation risk if sector sentiment cools, but also leaves room for the market to pay more for each yen of sales if the zasocitinib story and broader pipeline keep earning investor trust. Which of those readings do you think fits your own expectations best?

For a more numbers first view of this revenue based approach, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Comfortable with the overall optimism around Takeda Pharmaceutical or still on the fence and wanting your own angle before the crowd settles? Act fast, review both sides of the story, and weigh the 2 key rewards and 2 important warning signs.

Looking for more Takeda Pharmaceutical investment ideas?

Use this momentum around Takeda Pharmaceutical as a springboard. Broaden your watchlist with fresh angles so you are not relying on a single story.

• Target strong value potential by scanning a focused group of 14 high quality undervalued stocks that pair solid fundamentals with prices the market may not fully appreciate yet.
• Strengthen your income stream by reviewing a hand picked set of 32 dividend fortresses that combine higher yields with business profiles built for staying power.
• Dial down portfolio stress by filtering for 22 resilient stocks with low risk scores that show resilient financials and lower overall risk scores than the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com